News

Certara Simcyp™ Group Awarded Two New Grants from US FDA

Programs focus on use of physiologically-based pharmacokinetic (PBPK) modeling for demonstrating virtual bioequivalence and predicting drug absorption of topical formulationsPRINCETON,…

1 year ago

CMS grants reimbursement code for the Polarean XENOVIEW™ MRI Technology

The code is effective as of October 1, 2023Durham, NC, Aug. 29, 2023 (GLOBE NEWSWIRE) -- Polarean (AIM: POLX), a…

1 year ago

Ocean Biomedical (NASDAQ: OCEA) Announces New Patent for Anti-Fibrosis Discovery with Allowance in Alcoholic Liver Disease and Multiple Fibrotic Conditions, Leading Causes of Death in the U.S.

Ocean’s small molecule candidate significantly controls fibrosis progression in idiopathic pulmonary fibrosis (IPF) and Hermansky-Pudlak Syndrome (HPS) in multiple testing…

1 year ago

Olink to participate in September investor events

UPPSALA, Sweden, Aug. 29, 2023 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (“Olink”) (Nasdaq: OLK), today announced that Company management…

1 year ago

Vaxxinity to Present at Upcoming Investor Conferences in September

CAPE CANAVERAL, Fla., Aug. 29, 2023 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of…

1 year ago

InnovAge to Announce Fiscal Fourth Quarter 2023 Financial Results and Host Conference Call Tuesday, September 12, 2023

DENVER, Aug. 29, 2023 (GLOBE NEWSWIRE) -- InnovAge Holding Corp. (“InnovAge” or the “Company”) (Nasdaq: INNV), an industry leader in…

1 year ago

Better Life Partners Raises $26.5 Million in Series B Financing to Amplify and Scale its Hybrid Whole-Health Solutions for Substance Use Disorders

Funding will expand company’s technology-enabled, alternate-payment care model, bringing its innovative and effective approach to more people in needBOSTON, Aug.…

1 year ago

Morphic Announces Participation in 2023 Wells Fargo Healthcare Conference

WALTHAM, Mass., Aug. 29, 2023 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of…

1 year ago

Recce Pharmaceuticals Announces Safety Committee Approves Next Dose of RECCE® 327 at 3,000mg in Phase I/II UTI/Urosepsis Rapid Infusion Clinical Trial

Independent Safety Committee approves next cohort dosing of RECCE® 327 (R327) at two faster infusion rates of 3,000mg via IV…

1 year ago